• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Genomic Analysis Determines Post-Surgery Treatment in Prostate Cancer

Article

The results of the genomic data can guide treatment decisions post-surgery in prostate cancer.

A genomic classifier may be effective in predicting the risk of biochemical failure and distant metastasis in post-surgery radiation in patients with prostate cancer who have undergone radical prostatectomy, according to recent findings.

These findings suggest utility for a genomic classifier in deciding a patient’s course of treatment after radical prostatectomy, particularly in terms of identifying which patients will benefit from additional radiation.

“We are moving away from treating everyone the same,” researcher Robert Den, MD, assistant professor of radiation oncology and cancer biology at Thomas Jefferson University in Philadelphia, said in a press release. “Genomic tools are letting us gauge which cancers are more aggressive and should be treated earlier with radiation, and which ones are unlikely to benefit from additional therapy.”

Read the complete article: http://bit.ly/1q7xV9j

Source: Healio

Related Videos
Mila Felder, MD, FACEP
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Dr Lucy Langer
Edward Arrowsmith, MD, MPH
Dr Kathi Mooney
Tiago Biachi de Castria, MD, PhD, Moffitt Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.